Avenue Therapeutics (NASDAQ:ATXI) Announces Earnings Results, Beats Expectations By $0.05 EPS

Avenue Therapeutics (NASDAQ:ATXI) posted its quarterly earnings data on Wednesday. The company reported ($0.43) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.05, Bloomberg Earnings reports.

ATXI traded up $0.09 during trading on Thursday, reaching $6.00. 176 shares of the stock traded hands, compared to its average volume of 13,701. The stock has a market capitalization of $99.36 million, a PE ratio of -2.86 and a beta of -0.41. The company has a 50-day simple moving average of $6.04. Avenue Therapeutics has a 12 month low of $2.08 and a 12 month high of $7.98.

In related news, Director Neil Herskowitz acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, June 18th. The shares were bought at an average price of $5.86 per share, with a total value of $29,300.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Joseph Walter Vazzano sold 4,688 shares of the stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $5.59, for a total transaction of $26,205.92. Following the transaction, the chief financial officer now directly owns 59,038 shares in the company, valued at approximately $330,022.42. The disclosure for this sale can be found here. Corporate insiders own 5.00% of the company’s stock.

ATXI has been the subject of a number of recent research reports. ValuEngine upgraded Avenue Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Avenue Therapeutics in a research report on Tuesday, May 14th.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.

Further Reading: Street Name

Earnings History for Avenue Therapeutics (NASDAQ:ATXI)

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit